Anti-Mouse F4/80 – Purified in vivo GOLD™ Functional Grade
Anti-Mouse F4/80 – Purified in vivo GOLD™ Functional Grade
Product No.: F481
- -
- -
Clone Cl:A3-1 Target F4/80 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Adhesion G protein-coupled receptor E1 (ADGRE1), EMR1, F4/80, Gpf480 Isotype Rat IgG2b κ Applications FA , FC , ICC , IHC , IP , RIA |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Dilution Buffer Immunogen Thioglycolate-induced peritoneal macrophages from C57BL/6 mice Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? FA, FC, ICC, IHC, IP, RIA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Cl:A3-1 activity is directed against mouse F4/80. Background Macrophages play an important role in innate and adaptive immune system functions1. F4/80
antigen is a widely used cell-surface marker of murine macrophages1, 2 encoded by the Adgre1
locus3. F4/80 antigen is a G protein-coupled receptor with an extracellular domain containing
repeated Epidermal Growth Factor-like calcium-binding domains and as such is a member of the
EGF-TM7 protein family, which itself is a subfamily of the adhesion G protein-coupled receptors
(ADGRE) family. F4/80 is thought to have dual adhesion and signaling functions due to its
receptor domains and is known to be required for the differentiation of antigen-specific CD8+ T
regulatory cells1 . Adgre1 null mutant mice have a dysregulated autoimmune response and
regulatory T cell generation3. Additionally, unstimulated resting macrophages express F4/80 at
higher levels than activated macrophages1. Cl:A3-1 was generated by immunizing a rat with thioglycolate-induced peritoneal macrophages from C57BL/6 mice4. Spleen cells were fused with mouse myeloma cell line NS1. Cl:A3-1 does not bind to macrophages via Fc receptors and is not cytotoxic. Cl:A3-1 is able to modulate Listeria-induced cytokine signaling between macrophages and natural killer cells2. Antigen Distribution F4/80 is constitutively expressed on most macrophages, except those
located in T cell areas and marginal zones of lymph nodes and spleen, as well as on some
dendritic cells. Blood monocytes also express F4/80, but at low levels relative to mature
macrophages. Ligand/Receptor N/A NCBI Gene Bank ID UniProt.org Research Area Adaptive Immunity . Immunology . Signal Transduction References & Citations1 Lin HH, Faunce DE, Stacey M, et al. J Exp Med. 201(10):1615-1625. 2005. 2 Warschkau H, Kiderlen AF. J Immunol. 163(6):3409-16. 1999. 3 Waddell LA, Lefevre L, Bush SJ, et al. Front Immunol. 9:2246. 2018. 4 Austyn JM, Gordon S. Eur J Immunol. 11(10):805-815. 1981. 5 Hume DA, Perry VH, Gordon S. Anat Rec. 210(3):503-512. 1984. 6 Perry VH, Hume DA, Gordon S. Neuroscience. 15(2):313-326. 1985. 7 Morris L, Graham CF, Gordon S. Development. 112(2):517-526. 1991. 8 Haidl ID, Jefferies WA. Eur J Immunol. 26(5):1139-1146. 1996. Technical ProtocolsCertificate of Analysis |
Formats Available
